180 Life Sciences Corp Stock Price, News & Analysis

180 Life Sciences Corp. (NASDAQ: ATNF) has announced a new broadcast titled, “Controlling Inflammation to Stop Disease.” The company's research focuses on anti-TNF antibodies for autoimmune inflammatory diseases, suggesting significant market growth potential as new uses are identified. Ongoing clinical trials aim to address various disorders linked to inflammation. Collaborating with renowned institutions, 180 Life Sciences seeks to innovate treatments for unmet medical needs in inflammatory diseases. The company's lead program is currently in phase 2b/3 trials.

180 Life Sciences Corp. (NASDAQ: ATNF) has been featured in a NetworkNewsWire editorial titled "Controlling Inflammation to Stop Disease." This editorial highlights the significant link between inflammation and various health issues, which account for over 50% of global deaths. 180 Life Sciences is at the forefront of developing anti-inflammatory drugs, with its lead program in phase 2b/3 trials. The company is leveraging expertise from prestigious institutions like Oxford University and Stanford to create innovative therapies targeting unmet needs in inflammatory diseases, fibrosis, and pain.

180 Life Sciences Corp (NASDAQ: ATNF) outlines progress in a letter to stockholders from CEO Dr. James Woody. The company has successfully restated prior financials, completed an $11.7 million private placement, and reduced convertible debt from over $5 million to $316,000. They are adding independent directors to comply with NASDAQ requirements and aim to expedite clinical trials funded by grants. The pipeline includes a Phase 2b/3 trial for Dupuytren's contracture with expected results in the second half of 2021, targeting a market of over 22 million people in the US and EU.

180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology firm, announced its participation in the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. CEO Dr. James Woody will engage in one-on-one meetings with investors. The company focuses on innovative drug development targeting inflammatory diseases, fibrosis, and pain, with its lead program currently in Phase 2b/3 trials.

180 Life Sciences Corp. (NASDAQ: ATNF) announced the closing of a private placement of 2,564,000 shares and warrants, raising approximately $11.7 million. The shares are priced at $4.55 each, with warrants exercisable at $5.00. Proceeds will support corporate purposes, working capital, and drug development programs.

Maxim Group LLC was the sole placement agent for this transaction. The securities offered were only available to accredited investors and remain unregistered under the Securities Act of 1933.

180 Life Sciences Corp. (NASDAQ: ATNF) announced a private placement to raise approximately $11.7 million by issuing 2,564,000 shares of common stock at a price of $4.55 each, along with warrants. The exercise price for the warrants is $5.00, and they will expire in five years. Closing is expected on February 23, 2021. The offering targets accredited investors and includes a commitment to file registration statements with the SEC for resale of the shares and warrants.

180 Life Sciences Corp. (NASDAQ: ATNF) announced its participation in the H.C. Wainwright Bioconnect 2021 Conference, with on-demand presentations available between January 11-14, 2021. The clinical-stage biotechnology company focuses on developing novel drugs for inflammatory diseases, fibrosis, and pain, currently leading Phase 2b/3 trials targeting anti-TNF therapies. The presentation will be accessible via the company's website for up to 90 days post-conference.

180 Life Sciences Corp. (NASDAQ: ATNF) announced its participation in the LD Micro Virtual Main Event 2020 Conference on December 15, 2020, featuring CEO Dr. James Woody's presentation at 1:40 PM EST. The company focuses on developing drugs for inflammatory diseases, fibrosis, and pain, with its lead program currently in Phase 2b/3 trials. Their unique format includes 10 minutes of presentation followed by a 10-minute Q&A session. For registration, visit the specified link.

180 Life Sciences Corp. (NASDAQ: ATNF) announced its Nasdaq opening bell ceremony on November 27, 2020, celebrating its recent IPO. CEO Dr. James Woody and the team will participate virtually, emphasizing the company's focus on developing novel drugs for inflammatory diseases, fibrosis, and pain. The lead program is in Phase 2b/3 trials, leveraging expertise from renowned institutions. This milestone marks the company's transition to public status, showcasing its commitment to addressing unmet medical needs.